Spots Global Cancer Trial Database for A Rollover Study of Ixabepilone (BMS-247550) In Patients With Metastatic Breast Cancer Previously Treated With An Anthracycline
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Rollover Study of Ixabepilone (BMS-247550) In Patients With Metastatic Breast Cancer Previously Treated With An Anthracycline
Official Title: A Rollover Study of Ixabepilone (BMS-247550) In Patients With Metastatic Breast Cancer Previously Treated With An Anthracycline And Who Are Taxane Resistant Who Have Completed Study CA163107 And Who Are Benefiting From Continuation On Therapy With Ixabepilone
Study ID: NCT01027208
Conditions
Interventions
Study Description
Brief Summary: To provide extended access to Ixabepilone therapy to subjects with metastatic breast cancer who have completed the previous Phase II study (CA163-107)
Detailed Description:
Keywords
Eligibility
Minimum Age: 20 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Local Institution, Nagoya, Aichi, Japan
Local Institution, Kashiwa-Shi, Chiba, Japan
Local Institution, Fukuoka-Shi, Fukuoka, Japan
Local Institution, Matabashi-Shi, Gunma, Japan
Local Institution, Kagoshima-Shi, Kagoshima, Japan
Local Institution, Isehara-Shi, Kanagawa, Japan
Local Institution, Niigata-Shi, Niigata, Japan
Local Institution, Iruma-Gun, Saitama, Japan
Local Institution, Utsunomiya, Tochigi, Japan
Local Institution, Bunkyo-Ku, Tokyo, Japan
Local Institution, Chuo-Ku, Tokyo, Japan
Local Institution, Toshima-Ku, Tokyo, Japan
Local Institution, Saitama, , Japan
Local Institution, Tokyo, , Japan
Contact Details
Name: Bristol-Myers Squibb
Affiliation: Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
